Tag
Emerging therapies have revolutionized first-line treatment in large B-cell lymphoma, but inconsistent trial designs and biomarker use create complexity. Harmonized strategies integrating biomarkers, pooled data, AI, and regulatory collabor
A Sept 22, 2026 Annals of Oncology editorial from Stanford and University of South Carolina authors urges retiring 'negative' oncology names such as triple-negative breast cancer and non-small cell lung cancer in favour of molecularly defined entities, proposing hybrid transitional labels and biology-driven pathology reporting.
This study reveals that circulating tumor DNA (ctDNA) status after colorectal liver metastasis surgery predicts survival outcomes and benefits from adjuvant chemotherapy, guiding personalized treatment.
BRAF mutations occur in about 1% of AML and are usually non-V600 variants enriched in myelodysplasia-related disease. This cohort study found poor survival and suggested that current therapies, including venetoclax-based regimens, remain in
A real-world study of 671 endometrial cancer patients reveals significant molecular heterogeneity. PTEN, ARID1A, and PIK3CA are the most prevalent biomarkers, while TP53 mutations and ERBB2 amplification cluster in advanced-stage and non-en
The Phase 3 SONIA trial demonstrates that delaying CDK4/6 inhibitors to the second-line setting for advanced breast cancer yields comparable overall survival to first-line use, while significantly reducing treatment-related toxicities and h
This international multicenter study demonstrates that adjuvant imatinib therapy significantly improves both recurrence-free and overall survival in patients with resected KIT exon 9-mutant GIST, providing clarity on optimal management for
This review synthesizes findings from the Australian MoST program, demonstrating that genomically matched therapies significantly improve overall survival in advanced solid tumors only when supported by high-level prospective clinical trial
The Phase 3 SACHI trial demonstrates that the combination of savolitinib and osimertinib significantly extends progression-free survival compared to chemotherapy in patients with MET-amplified, EGFR-mutated non-small-cell lung cancer who pr
A massive cohort study reveals that colorectal adenoma recurrence risk is not static; high-grade dysplasia, villous histology, obesity, and sex-based factors exhibit distinct time-varying patterns, necessitating a shift toward personalized,
The Phase III CANOVA trial evaluated venetoclax-dexamethasone against pomalidomide-dexamethasone in t(11;14)-positive RRMM. While the primary endpoint of progression-free survival was not statistically met, the study revealed significant im
A Phase 1 study and preclinical analysis reveal that inavolisib, a PI3Kα inhibitor and degrader, leverages FGFR2 signaling to enhance the degradation of mutated p110α, yielding superior clinical benefits in PIK3CA-mutated solid tumors.
Researchers have developed a machine learning model using real-world and clinical trial data to predict distant recurrence risk and ribociclib’s therapeutic effect in HR+/HER2- early breast cancer, offering a potential tool for person
A multi-institutional analysis reveals that HER2-positivity in advanced biliary tract cancer signals a poorer prognosis but offers a significant survival benefit when targeted with anti-HER2 therapies, advocating for routine screening and s
A large-scale clinico-genomic study confirms that both tissue-based TMB and MSI-H independently predict significantly improved outcomes for ICI therapy in metastatic castration-resistant prostate cancer, while also validating blood-based MS
A landmark study reveals that FET-rearranged myoepithelial tumors are epigenetically distinct from PLAG1-rearranged salivary and adnexal variants, suggesting they are closer to sarcomas than carcinomas, with significant clinical implication
A large-scale clinico-genomic study demonstrates that both tissue-based MSI-H and TMB-H status independently predict superior outcomes for immune checkpoint inhibitors in mCRPC, while validating blood-based MSI as a viable alternative for p
A pooled analysis of the RAGNAR and LUC2001 trials demonstrates that erdafitinib provides a robust objective response rate of 55% and a median overall survival of 18.1 months in pretreated patients with FGFR-altered advanced cholangiocarcin
A French national study demonstrates that molecularly-guided treatments, facilitated by a dedicated multidisciplinary tumour board, significantly improve survival for patients with cancer of unknown primary, extending median overall surviva
This systematic review and network meta-analysis of 20 randomized trials demonstrate that molecular profiling for ESR1 and PI3K-AKT-PTEN alterations is essential for optimizing endocrine-based strategies after CDK4/6 inhibitor progression,
